Global Antacids Market

Comments · 27 Views

global antacids market is projected to grow significantly, reaching US$ 9.70 billion by 2032, up from US$ 6.88 billion in 2023, representing a CAGR of 3.89% from 2024 to 2032

The global antacids market is projected to grow significantly, reaching US$ 9.70 billion by 2032, up from US$ 6.88 billion in 2023, representing a CAGR of 3.89% from 2024 to 2032. This growth is fueled by increasing health concerns such as gastroesophageal reflux disease (GERD), changing demographics with a rising elderly population, and the growing trend of self-medication. Antacids continue to be a popular and effective solution for managing digestive discomforts such as heartburn, acid reflux, and indigestion.

Request a free sample copy of the report: https://www.renub.com/antacids-market-p.php

Market Outlook: What Are Antacids?

Antacids are medications that neutralize stomach acid, providing quick relief from symptoms such as heartburn, indigestion, and acid reflux. They work by raising the pH level in the stomach, making the stomach contents less acidic and soothing the painful burning sensations that result from high stomach acidity.

Because they are available over-the-counter (OTC), antacids are widely accessible and easy to use. They come in various forms, including chewable tablets, liquids, and effervescent powders, catering to different preferences and offering fast-acting relief. Antacids are popular among people seeking self-treatment for mild and intermittent digestive issues, making them a staple in households worldwide.

Market Drivers

1. Rising Prevalence of GERD

Gastroesophageal reflux disease (GERD) is a major driver of the antacids market. GERD is a chronic digestive condition where stomach acid frequently flows back into the esophagus, causing heartburn and other discomforts. According to a 2022 National Library of Medicine report, over 783 million people globally were affected by GERD in 2019. The increasing number of GERD sufferers contributes directly to the growing demand for antacids. These medications are often the first line of defense for people dealing with frequent acid reflux and other gastrointestinal problems.

2. Aging Population and Digestive Health

The global aging population is another key factor influencing the antacid market. As people age, they tend to experience more digestive issues, including acid reflux and heartburn, which are commonly treated with antacids. The World Health Organization (WHO) reports that by 2050, the number of people aged 60 and above will more than double, reaching 2.1 billion. Older individuals are more likely to suffer from digestive disorders, driving higher consumption of over-the-counter products like antacids.

The increased usage of antacids among the elderly is expected to continue rising as the population of older adults expands, especially in regions like North America and Europe.

3. Self-Medication Trends

A growing preference for self-medication has also boosted the demand for antacids, particularly in North America. Consumers are becoming more proactive about managing mild health issues on their own, without the need for prescription drugs or doctor visits. With their easy availability in pharmacies and supermarkets, antacids provide an accessible solution for treating common gastrointestinal complaints, supporting their widespread use.

4. Diet and Lifestyle Changes

Changes in diet and lifestyle, such as higher consumption of processed foods, larger portion sizes, and increased stress levels, are contributing to the rise in gastrointestinal disorders. These factors exacerbate the incidence of heartburn and acid reflux, increasing the need for antacids to manage these conditions.

Regional Insights: North America Leading the Market

North America holds a significant share of the global antacids market, driven by a combination of high GERD prevalence and a culture of self-medication. According to a 2022 study, 10–20% of Americans experience GERD symptoms on a weekly basis, leading to a strong demand for products that can provide relief from heartburn and acid reflux.

The market in North America is also bolstered by regulatory approvals and product innovations. For instance, in June 2022, Zydus Lifesciences received approval from the U.S. FDA to sell famotidine tablets, a common antacid used to reduce stomach acid. Similarly, a growing number of pharmaceutical and consumer health companies are expanding their antacid offerings to meet the rising demand for digestive health products.

Competitive Landscape: Leading Companies

Several major companies dominate the global antacids market, offering a wide range of products to cater to different customer needs:

  • Abbott Laboratories
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Dr. Reddy’s Laboratories Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Pfizer Inc.
  • Procter & Gamble Company
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited

These companies have developed popular antacid brands and continue to invest in research and development (R&D) to create new and improved formulations for treating acid-related digestive issues.

Recent Developments in the Antacids Market

  1. March 2024: ENO, a leading digestion brand formerly owned by GSK Consumer Healthcare and now part of Haleon, launched "ENO Chewy Bites". The new product comes in two flavors—Tangy Lemon and Zesty Orange—providing consumers with a convenient, chewable option to manage stomach discomfort. This expansion reflects the market’s trend toward offering more variety and flexibility in dosage forms.
  2. March 2023: Wonderbelly, a company focusing on clean ingredients for digestive health, introduced its new Wonderbelly Antacid Chewable Tablets. These tablets are designed to offer an effective, clean-label solution for people seeking relief from heartburn and indigestion.
  3. February 2022: Procter & Gamble (P&G) introduced an updated formula for their Pepto-Bismol line, including a more potent antacid option for fast-acting relief from stomach upset.
  4. May 2021: Sanofi expanded its TUMS product range with new, more powerful antacid tablets aimed at providing stronger and longer-lasting relief for severe heartburn.

Related Report :

Chronic Obstructive Pulmonary Disease (COPD) Market

Hormone Replacement Therapy Market

Global Antacids Market

About the Company:

Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.

Media Contact:

Company Name: Renub Research

Contact Person: Rajat Gupta, Marketing Manager

Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)

Email: mailto:rajat@renub.com

Comments